JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results - ASCO 2011
COMFORT-II, the second pivotal Phase III trial of the Janus kinase, or JAK inhibitor ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, or MF, when compared to best available therapy. The European study, called COMFORT-II showed treatment with ruxolitinib provided a statistically significant reduction in spleen size in patients with primary MF, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, when compared with best available therapy, administered at doses and schedules determined by the investigator. The safety profile of ruxolitinib was consistent with previous studies. Discussed at ASCO 2011.